ValuePickr Forum

Granules India Ltd

Dividend or buyback now are equally good/bad, tax-wise. I would prefer buyback since pool of shares is reduced and everyone benefits including future buyers. Though process is more cumbersome, it gives option to not participate, democratic.

But here they should payback their loans instead with the 200 Cr. Should reject buyback after voting, hopefully.

1 Like
  1. Midcaps are known to blow up cash in pursuing overpaid inorganic growth (and the Goodwill that exists on paper mostly) or divert money to subsidiaries/ private companies of promoters etc.

  2. When the shares were trading lower, the management didn’t have cash to buyback. When they have the cash, there’s LTCG on the stake sale topped by the buyback tax is a painful double whammy.

  3. In a way, it is better to buyback than to blow cash up by getting seduced into doing different things. But paying off debts is always safer.

I hope that they take all shareholders on board and exhibit good corporate behavior in dealing with this. If the prime motive is to reduce pledge by cashing in on a high buyback price, the stock’s post buyback price move may get impacted.

5 Likes

Next few days till 21st are going to make Granules investors busy / fingers crossed.

Q3 result and analyst / investor call is scheduled on same day, which confirms that results will be declared during market hours. As per management guidelines, the results should be good to ignite more fireworks.

Investor call details

2 Likes

During the last concall no questions were taken from any retail investor. Hope this time at least they do it subject to availability of time.

Granules most of the debt is in foreign currency and has very low interest rate. Management has clarified this many times that it doesn’t make sense to pay off this debt instead if they do deposit, it will fetch higher returns. Since Granules is done with majority of it’s capex, the only few options were divided, buyback or fd. With the kind of growth company has shown, the stock is still undervalued. Still 30% shares are pledged. With this buyback and good growth in coming quarters, management might be thinking that market will take stock price higher and then they should be able to release few more pledged shares. I don’t think this is a bad move.

2 Likes

In fy19, they paid 28 cr interest for 991cr borrowing. i.e. 2.8%

1 Like

Is Granules in the business of drug manufacturing or earnings interest income on bank deposits? If it was so simple, why other Companies are not practicing this simple trick?

3 Likes

I read here that the company itself admits to not disclosing interest costs but putting them under head of capital expenditure. There is some commitment from them to reduce this in order to stop doing this fully by FY21.

Doing simple arithmetic then indeed it looks to be 2-3 % interest rate but that is almost equal to Libor. Do not think they are the Bank of America to borrow at par with Libor or lower. Their rate is Libor linked but premium to that. I suppose it will work out easily to almost double or more of Libor. It should reasonably be 7% around. Or else they should be invited to teach other Indian companies facing borrowing crisis. :sweat_smile:

2 Likes

Buyback size : 4.92% of total paid-up equity capital

250 Cr at 200/- per share (approx 33% above current valuation)

Q3 results : https://www.bseindia.com/xml-data/corpfiling/AttachLive/13e1223a-8574-416e-99f8-996a1851b083.pdf

Q3 Investor Presentation : https://www.bseindia.com/xml-data/corpfiling/AttachLive/acec87d2-0471-46bb-8c53-144bce8895f0.pdf

  • Net Profit during the quarter was impacted due to a one-time impairment of ~INR 32.03 Cr provided for Biocause.
  • Declared third interim dividend of 25 paise per share of face value of Re. 1/- each representing 25% of paid-up capital for the financial year 2019-20;
  • Fixed the record date as 31st January 2020 for the purpose of payment of third interim
    dividend for the financial year 2019-20.

Q3 Concall notes

  • Expecting ~200 Cr from JV exit - would be used for buyback
  • FCF till Q3 154 cr - will achieve internal targets for the year
  • Gross debt 902 cr / net debt - 789 cr
  • GPI - Revenue 88.72 Cr / EBITDA 19.38 Cr /PAT 3.45 Cr
  • Main focus on FCF & ROCE & Bottom line
  • Expect increase in working capital due to own marketing efforts in US
  • buyback reason : Reward share holder / didn’t payback debt as we hardly pay 1.5% interest rate
  • Promoter group would be participating in buyback which will help reducing pledge - pledge will reduce to 5-6% (current levels are 30.56%)
  • EBITDA - 20% plus is achievable for next atleast 4-6 quarters
  • There could be slight reduction in Gross / Net debt even after buyback as few payments are planned in near future
  • Debt reduction : will be approx 100 cr debt reduction each year as per repayment plan
  • Can take more debt when DEBT / EBITDA ratio is below 1, if we get better opportunities & need funds for capex
  • R&D are being directly charged from this quarter - some part of ongoing activities can be capitalized but slowly moving to charging each quarter
13 Likes

Good results overall, and good to see that despite selling off both Omnichem and Biocause, the earnings growth has not slowed down. Some notes
1- During Capex cycle last 3-4 years multiple times there was doubt if the management is taking multiple risks in one shot. However now it seems that the risks taken have started paying back.
2- One can question if doing away with both JVs was right decision. But now we are past it. And I guess no one can deny that this disinvestment would help management focus on mother ship better.
3- I am confused about the decision of buy back. With 900 crores of debt on the books I still think that the right thing to do would be to reduce the debt. But then I am not an expert. All I know is that if the Crude again goes up to $80 and above ( which has happened couple of times in last few years) then even paying 3% of interest would start weighing down the earnings considerably.
4- Keeping buy back aside, I like few things company is doing - focus on free cash flow, debt reduction and pledge reduction.
5- Formulations have gradually gone beyond half mark contributing to the business. So Granules the company which provides APIs for generics is changing fast.
6- The current upthrust in topline and bottom line should sustain for next couple of years because of sales moving from EMs to regulated markets and better sweating of newly built assets. The better mix towards FDs, selling OTC drugs in US, and new drug launches should also help. After two years the Onco APIs should provide the next kick.
7- Key risks in my opinion are

  • Crude prices going up
  • High debt on the books. Working capital increase will make it look worse.
  • Poor execution of plan including launch of Onco APIs ( tough nut to crack based on the little I know about this segment).

I am invested, and my views could be biased.

Cheers,
Krishna

10 Likes

Very accurately summed up.
Buy back at this stage should enable the family to get rid of pledges in one go without any dilution of equity holding.

Screener.in shows DE as 0.5 already. Is it incorrect? Why is this so?

The refer Debt / EBITDA ratio

image

1 Like

Granules Q3 Conference call updates:

  1. Guidance of 20% revenue growth and 25% profit growth for three years.

  2. R&D expenses are being fully expensed from this quarter

  3. Guidance of annual capex of 150cr

  4. Working capital may increase going forward due to high inventory requirement in US Generic business

  5. Granules plans to file 20-25 ANDAs in the next three years

  6. Buyback to reduce promoter pledge to 5%

  7. Company plans to reduce debt going ahead even after the buyback

  8. Metformin plant has got USFDA approval. Company to use in house API. This will aid margins.

  9. Vizag plant to break even in FY20-21 and contribute to profits only in FY21-22

  10. Company can grow without capex for next two - three years. Post that will need to capex to grow.

Disclosure: Invested

3 Likes

MGT said in the concall that their pledge will come down to negligible 5 percent, but rough calculation shows that they still have 4 cr shares pledged , so out 25.42 cr eq, they have 43 percent holding ,sothat comes to 10 cr shares now come to buyback which is 5 percent so they are entitled to 50 lakhs shares so roughly they get 100 cr from buyback now pledge of 4 crshares amt to 350cr if v take price of 90 that math MGT is saying is not matching as per my calculations , correct me if i m wrong , views invited

Ballpark numbers:
Today’s market cap Rs 3800 crs
Same pledge was there when share price was roughly half (c. Rs 75-80) i.e. c. 1900 crs
Value of promoter pledged shares at that time 1900*43%*37% = 300 crs
Typical cover on loan against shares 2x, roughly INR 150 crs loan outstanding at promoter level

In buyback promoters will get 10 cr shares * 200* c. 5% = 100 crs
Loan remaining c. Rs 50 crs
Pledge required @ 2x c. Rs 100 crs
As a % of promoter shareholding 100 / (3800*43%)= c. 6%

6 Likes

Ok , thanks for clearly explaining i forgot to give the discount of 40 percent on pledge shares

1 Like

As per the AR18-19 following are the outstanding loans. Loans taken before 2014 have rate of ~Libor +4% and latest loans have rate of ~LIBOR+2.75. But, Mr. Krishna Prasad mentioned in the latest call that interest rate is around ~1.5%. Wrote an email to the company. Let’s see what they will say.

2 Likes

My bad …Latest loans are in EURIBOR. Per google, current 12 month EURIBOR rate is -0.25%. So, effective rate is ~ 2.5% in EURO.

1 Like